Skip to main content

Table 4 Bi-variate and multi-variate logistic regression analysis of patients on anti-thrombotic therapy at Cardiac Clinic, UOG hospital, Northwest Ethiopia, December 1, 2018 to September 30, 2019

From: Appropriate use of anti-thrombotic therapy in patients with atrial fibrillation at single-center experience, Northwest Ethiopia

Variable

Anti-thrombotic therapy Appro. Inappro.

COR (95%)

P-value

AOR (95%)

P-Value

Stroke

 Yes

33 6

3.46 (1.37–8.70)

0.008

2.20 (0.56–8.70)

0.25

 No

105 66

    

Type of AF

 Valvular

58 16

3.09 (1.58–6.07)

0.001

1.90 (0.80–4.80)

0.14

 Non-valvular

81 55

    

INR monitoring

vCan afford

135 56

8.82 (2.80–27.72)

< 0.001

2.60 (1.10–6.10)

0.001

 Can’t afford

4 15

    

Heart failure

 Yes

124 66

0.8 (0.46–3.40)

0.67

  

 No

14 6

    

Hypertension

 

0.8 (0.73–3.0)

   

 Yes

34 13

 

0.28

  

 No

104 59

    

Thyrotoxicosis

 Yes

19 19

0.45 (0.22–0.90)

0.026

0.80 (0.40–1.90)

0.67

 No

119 53

    

Age (years)

  ≥ 75

15 3

2.80 (0.78–10.03)

0.13

2.20 (0.50–8.70)

0.25

  < 75

123 69

    

Place of Residence

 Urban

68 34

1.08 (0.50–1.60)

0.77

  

 Rural

70 38

    

Formal education

 Yes

101 56

0.78 (0.60–2.50)

0.41

  

 No

37 16

    
  1. Note: AF atrial fibrillation, COR crude odds ratio, AOR adjusted odds ratio